Ibogaine: a potent noncompetitive blocker of ganglionic/neuronal nicotinic receptors.
暂无分享,去创建一个
[1] A. Lajtha,et al. The effect of ibogaine on sigma- and NMDA-receptor- mediated release of [3H]dopamine , 1996, Brain Research Bulletin.
[2] P. Skolnick,et al. Structurally modified ibogaine analogs exhibit differing affinities for NMDA receptors. , 1996, European journal of pharmacology.
[3] P. Skolnick,et al. The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence , 1996, Pharmacology Biochemistry and Behavior.
[4] S. D. Glick,et al. Ibogaine-like effects of noribogaine in rats , 1996, Brain Research.
[5] M. Benwell,et al. Neurochemical and behavioural interactions between ibogaine and nicotine in the rat , 1996, British journal of pharmacology.
[6] M. Reuben,et al. Release of [3H]‐noradrenaline from rat hippocampal synaptosomes by nicotine: mediation by different nicotinic receptor subtypes from striatal [3H]‐dopamine release , 1996, British journal of pharmacology.
[7] A. Lajtha,et al. The effect of ibogaine on κ-opioid- and 5-HT3-induced changes in stimulation-evoked dopamine release in vitro from striatum of C57BL/6BY mice , 1995, Brain Research Bulletin.
[8] P. Skolnick,et al. NMDA antagonist properties of the putative antiaddictive drug, ibogaine. , 1995, The Journal of pharmacology and experimental therapeutics.
[9] E. Codd. High affinity ibogaine binding to a mu opioid agonist site. , 1995, Life sciences.
[10] D. Shi,et al. Antinociceptive effects of the alkaloid epibatidine: Further studies on involvement of nicotinic receptors , 1995 .
[11] R. Mach,et al. Ibogaine possesses a selective affinity for σ2 receptors , 1995 .
[12] P. Skolnick,et al. 100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. , 1995, Pharmacological reviews.
[13] S. D. Glick,et al. Radioligand-binding study of noribogaine, a likely metabolite of ibogaine , 1995, Brain Research.
[14] M. Damaj,et al. Pharmacological effects of epibatidine optical enantiomers , 1994, Brain Research.
[15] J. Daly,et al. Epibatidine, a potent analgetic and nicotinic agonist. , 1994, Molecular pharmacology.
[16] P. Clarke,et al. The pharmacology of the nicotinic antagonist, chlorisondamine, investigated in rat brain and autonomic ganglion , 1994, British journal of pharmacology.
[17] P. Clarke,et al. Blockade of nicotinic receptor‐mediated release of dopamine from striatal synaptosomes by chlorisondamine and other nicotinic antagonists administered in vitro , 1994, British journal of pharmacology.
[18] B. Francés,et al. Effects of ibogaine on naloxone‐precipitated withdrawal in morphine‐dependent mice , 1992, Fundamental & clinical pharmacology.
[19] S. D. Glick,et al. Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies , 1992, Brain Research.
[20] J. Carlson,et al. Effects and aftereffects of ibogaine on morphine self-administration in rats. , 1991, European journal of pharmacology.
[21] G. Wardeh,et al. κ and δ-opioid receptor agonists differentially inhibit striatal dopamine and acetylcholine release , 1984, Nature.
[22] E. Albuquerque,et al. Mechanism of action of amantadine on neuromuscular transmission. , 1978, Molecular pharmacology.
[23] D. Donnelly-roberts,et al. Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor. , 1996, The Journal of pharmacology and experimental therapeutics.
[24] W. Bowen,et al. Ibogaine and its congeners are sigma 2 receptor-selective ligands with moderate affinity. , 1995, European Journal of Pharmacology.
[25] A. Lajtha,et al. Ibogaine antagonizes cocaine-induced locomotor stimulation in mice. , 1992, Life sciences.